(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 November 2010 (04.11.2010)

PCT

(10) International Publication Number
WO 2010/125014 A1

(51) International Patent Classification:
A61K 39/10 (2006.01)

(21) International Application Number:
PCT/EP2010/055507

(22) International Filing Date:
26 April 2010 (26.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09305371.8 28 April 2009 (28.04.2009) EP

(71) Applicants *(for all designated States except US)*: **INSERM (Institut National de la Santé et de la Recherche Médicale)** [FR/FR]; 101, rue de Tolbiac, Paris, 75013 (FR). **INSTITUT PASTEUR DE LILLE** [FR/FR]; 1 Rue du Professeur Calmette 59800 LILLE, F-59800 Lille (FR). **NATIONAL UNIVERSITY OF IRELAND MAYNOOTH** [IE/IE]; Maynooth, Co., Kildare (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LOCHT, Camille** [—/FR]; 1, rue du Professeur Calmette - BP 447 Département de pathogénèse des maladies infectieuses, F-59021 Lille Cedex (FR). **MAHON, Bernard** [GB/IE]; National University of Ireland Maynooth County Kildare, Maynooth (IE). **KAVANAGH, Heather** [GB/IE]; National University of Ireland Maynooth County Kildare, Maynooth (IE).

(74) Agents: **CABINET PLASSERAUD** et al.; 52 rue de la Victoire, F-75440 Paris Cedex 09 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2010/125014 A1

(54) Title: VACCINE FOR PROPHYLAXIS OR TREATMENT OF AN ALLERGEN-DRIVEN AIRWAY PATHOLOGY

(57) Abstract: The present invention relates to a life attenuated *Bordetella* pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.